Innate immune control of nucleic acid-based vaccine immunogenicity

Expert Review of Vaccines

Volumn 8, Issue 8, 2009, Pages 1099-1107

  Koyama, Shohei ^a,b   Coban, Cevayir ^a,c   Aoshi, Taiki ^c   Horii, Toshihiro ^c   Akira, Shizuo ^a,c   Ishii, Ken J ^a,c  

^a OSAKA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Innate immunity; Nucleic acid; Vaccine adjuvant

Indexed keywords

DNA VACCINE; NUCLEIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; VACCINE;

ADJUVANT THERAPY; B LYMPHOCYTE; CELL TYPE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENDOSOME; GENETIC IMMUNIZATION; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; HUMANS; IMMUNITY, INNATE; NUCLEIC ACIDS; VACCINES, DNA; VIRAL VACCINES;

EID: 68049118485     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.57     Document Type: Review

References (81)

1. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 20, S7-S12 (2002).
2. Rappuoli R. Bridging the knowledge gaps in vaccine design. Nat. Biotechnol. 25, 1361-1366 (2007).
3. Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 124, 849-863 (2006). •• Discusses the importance of innate immunity manipulation for vaccine immunogenicity.
4. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11, S63-S68 (2005).
5. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311, 17-58 (2006).
6. Ishii KJ, Akira S. Toll or Toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27, 363-371 (2007).
7. Ishii KJ, Koyama S, Nakagawa A et al. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 3, 352-363 (2008).
8. Alexopoulou L, Holt AC, Medzhitov R et al. Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3. Nature 413, 732-738 (2001).
9. Kleinman ME, Yamada K, Takeda A et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
10. Diebold SS. Recognition of viral singlestranded RNA by Toll-like receptors. Adv. Drug Deliv. Rev. 60, 813-823 (2008).
11. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
12. Haas T, Metzger J, Schmitz F et al. The DNA sugar backbone 2́-deoxyribose determines Toll-like receptor 9 activation. Immunity 28, 315-323 (2008).
13. Hou B, Reizis B, Defranco AL. Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms. Immunity 29, 272-282 (2008).
14. Koyama S, Ishii KJ, Coban C et al. Innate immune response to viral infection. Cytokine 43, 336-341 (2008).
15. Pichlmair A, Schulz O, Tan CP et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5́-phosphates. Science 314, 997-1001 (2006).
16. Kato H, Takeuchi O, Mikamo-Satoh E et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205, 1601-1610 (2008).
17. Kawai T, Takahashi K, Sato S et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
18. Seth RB, Sun L, Ea CK et al. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kB and IRF 3. Cell 122, 669-682 (2005).
19. Meylan E, Curran J, Hofmann K et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167-1172 (2005).
20. Xu LG, Wang YY, Han KJ et al. VISA is an adapter protein required for virus-triggered IFN-b signaling. Mol. Cell 19, 727-740 (2005).
21. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signaling. Nature 455, 674-678 (2008).
22. Zhong B, Yang Y, Li S et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 4, 538-550 (2008).
23. Sun W, Li Y, Chen L et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc. Natl Acad. Sci. USA 106(21), 8653-8658 (2009).
24. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 442, 39-44 (2006).
25. Masumoto J, Zhou W, Chen FF et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 274, 33835-33838 (1999).
26. Franchi L, Eigenbrod T, Muñoz-Planillo R et al. The inflammasome: a caspase-1- activation platform that regulates immune responses and disease pathogenesis. Nat. Immunol. 10, 241-247 (2009).
27. Kanneganti TD, Ozoren N, Body-Malapel M et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233-236 (2006). • This report, together with [26], demonstrates that NALP3-dependent inflammasome activation is involved in microbial RNA recognition.
28. Kanneganti TD, Body-Malapel M, Amer A et al. Critical role for cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281, 36560-36568 (2006).
29. Rotem Z, Cox RA, Isaacs A. Inhibition of virus multiplication by foreign nucleic acid. Nature 197, 564-1546 (1963).
30. Suzuki K, Mori A, Ishii KJ et al. Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. Proc. Natl Acad. Sci. USA 96(5), 2285-2290 (1999).
31. Ishii KJ, Coban C, Kato H et al. A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 7, 40-48 (2006).
32. Stetson DB, Medzhitov R. Recognition of cytosolic DNA activates an IRF3- dependent innate immune response. Immunity 24, 93-103 (2006).
33. Ishii KJ, Kawagoe T, Koyama S et al. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 451, 725-729 (2008). •• Demonstrates that DNA vaccine immunogenicity is dominantly regulated by the TANK-binding kinase 1-dependent pathway, but not the Toll-like receptor-9-dependent pathway.
34. Muruve DA, Petrilli V, Zaiss AK et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103-107 (2008).
35. Roberts TL, Idris A, Dunn JA et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323(5917), 1057-1060 (2009). • This report, together with [34,36] shows a novel molecule that is involved in DNA sensing and induction of NALP3- independent inflammasome activation.
36. Hornung V, Ablasser A, Charrel-Dennis M et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458(7237), 514-518 (2009).
37. Fernandes-Alnemri T, Yu JW, Datta P et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458(7237), 509-513 (2009).
38. Bürckstümmer T, Baumann C, Blüml S et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol. 3, 266-272 (2009).
39. Kato H, Takeuchi O, Sato S et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
40. Kumar H, Koyama S, Ishii KJ et al. Cooperation of IPS-1- and TRIFdependent pathways in poly IC-enhanced antibody production and cytotoxic T-cell responses. J. Immunol. 180, 683-687 (2008).
41. Lopez CB, Moltedo B, Alexopoulou L et al. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J. Immunol. 173, 6882-6889 (2004).
42. Heer AK, Shamshiev A, Donda A et al. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178, 2182-2191 (2007).
43. Koyama S, Ishii KJ, Kumar H et al. Differential role of TLR- and RLRsignaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179, 4711-4720 (2007).
44. Ichinohe T, Lee HK, Ogura Y et al. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206, 79-87 (2009).
45. Thomas PG, Dash P, Aldridge JR Jr et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 4, 566-575 (2009).
46. Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA. Immunity 4, 556-565 (2009).
47. Geeraedts F, Goutagny N, Hornung V et al. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS. Pathog. 4(8), e1000138 (2008).
48. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006).
49. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927-974 (2000).
50. Coban C, Koyama S, Takeshita F et al. Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin. 4(6), 453-456 (2008).
51. Spies B, Hochrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol. 171, 5908-5912 (2003).
52. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 60(8), 915-928 (2008).
53. Scheerlinck JP, Greenwood DL. Virussized vaccine delivery systems. Drug Discov. Today 19/20, 882-887 (2008).
54. Sanders MT, Brown LE, Deliyannis G et al. ISCOM-based vaccines: the second decade. Immunol. Cell Biol. 2, 119-128 (2005).
55. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004).
56. Zwiorek K, Bourquin C, Battiany J et al. Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 3, 551-562 (2008).
57. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7, 179-190 (2007).
58. Roelofs MF, Joosten LA, Abdollahi- Roodsaz S et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52, 2313-2322 (2005).
59. Napolitani G, Rinaldi A, Bertoni F et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769-776 (2005). • This report, together with [56,58] shows that innate immune receptor ligands could be combined to induce either synergy or tolerance.
60. Bagchi A, Herrup EA, Warren HS et al. MyD88-dependent and MyD88- independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178, 1164-1171 (2007).
61. van Heel DA, Ghosh S, Hunt KA et al. Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut 54, 1553-1557 (2005).
62. He H, Genovese KJ, Nisbet DJ et al. Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes. Mol. Immunol. 12, 3234-3242 (2007).
63. Wack A, Baudner BC, Hilbert AK et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 4, 552-561 (2008).
64. Pichichero ME. Improving vaccine delivery using novel adjuvant systems. Hum. Vaccine 4, 262-270 (2008).
65. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell Mol. Life Sci. 20, 3231-3240 (2008).
66. Oma K, Jizi Z, Hirokazu E et al. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine (2009) (In Press).
67. Oliveira ML, Arêas AP, Ho PL. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev. Vaccines 6(3), 419-429 (2007).
68. Song JH, Nguyen HH, Cuburu N et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc. Natl Acad. Sci. USA 105(5), 1644-1649 (2008).
69. Genescà M, Skinner PJ, Bost KM et al. Protective attenuated lentivirus immunization induces SIV-specific T cells in the genital tract of rhesus monkeys. Mucosal Immunol. 3, 219-228 (2008).
70. Kim-Schulze S, Kim HS, Wainstein A et al. Intrarectal vaccination with recombinant vaccinia virus expressing carcinoembryonic antigen induces mucosal and systemic immunity and prevents progression of colorectal cancer. J. Immunol. 11, 8112-8119 (2008).
71. Adams M, Navabi H, Jasani B et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21, 787-790 (2003).
72. Ichinohe T, Tamura S, Kawaguchi A et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196, 1313-1320 (2007).
73. Jin B, Wang RY, Qiu Q et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology 122, 15-27 (2007).
74. Fujimura T, Nakagawa S, Ohtani T et al. Inhibitory effect of the polyinosinicpolycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol. 36, 3371-3380 (2006).
75. Adams S, O'Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol. 181, 776-784 (2008).
76. Wu JJ, Huang DB, Tyring SK. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res. 64, 79-83 (2004).
77. Wille-Reece U, Flynn BJ, Loré K et al. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203, 1249-1258 (2006).
78. Johnston D, Zaidi B, Bystryn JC. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol. Immunother. 56, 1133-1141 (2007).
79. Vajdy M, Selby M, Medina-Selby A et al. Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J. Gen. Virol. 87, 2253-2262 (2006).
80. Zaks K, Jordan M, Guth A et al. Efficient immunization and crosspriming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176, 7335-7345 (2006).
81. Hornung V, Ellegast J, Kim S et al. 5́-triphosphate RNA is the ligand for RIG-I. Science 314, 994-997 (2006).